“Latest Stem Cells News”

AUGUSTA, Ga. – Medical College of Georgia researchers are conducting the first FDA-approved clinical trial to determine whether an infusion of stem cells from umbilical cord blood can improve the quality of life for children with cerebral palsy.

The study will include 40 children age 2-12 whose parents have stored cord blood at the Cord Blood Registry in Tucson, Ariz.
Umbilical cord blood is rich in stem cells, which can divide and morph into different types of cells throughout the body, said Dr. James Carroll, professor and chief of pediatric neurology in MCG School of Medicine and principal investigator on the study.

Cerebral palsy, caused by a brain injury or lack of oxygen in the brain before birth or during the first few years of life, can impair movement, learning, hearing, vision and cognitive skills. Two to 3 children in 1,000 are affected by it, according to the Centers for Disease Control.
Animal studies indicate that infused stem cells help injured brain cells recover and replace brain cells that have died, Dr. Carroll said.

A particular type of stem cell transplantation using the patient’s own cells led to short-term freedom from insulin injections in 20 of 23 patients newly diagnosed with type 1 diabetes participating in an experimental protocol in Brazil.

One patient even managed to go four years without needing outside sources of insulin, although the average was 31 months, said the authors of a report in the April 15 issue of the Journal of the American Medical Association, a themed issue on diabetes.

The patients also kept their blood sugar under control, which is key to preventing complications from diabetes. And, the authors stated, increased C-peptide levels indicated that the pancreas’ beta cells were alive and well.

“We were trying to preserve islet beta cell mass, that is, the cells that produce insulin, by stopping the immune system attack on these cells,” said senior study author Dr. Richard Burt, of Northwestern University Feinberg School of Medicine in Chicago. “Why new onset? Because we wanted to make sure there were still some islets there. We don’t believe stem cells form islet cells, but if the islet cells are still there, there might be regeneration if we stop the attack soon enough.”

A team of doctors of haematology department of Nilratan Sircar Medical College and Hospital performed a blood stem cell transplantation on a patient wherein they successfully re-infused blood stem cells into a patient’s bloodstream on 30 January. The patient is suffering from a type of blood cancer known as multiple myeloma.
Mrs Bela Samanta, a resident of Burdwan, has been a patient of leukaemia for past one year. On 16 December she was admitted to the hospital in a critical condition. Doctors examined her and said there was a need for this transplantation, if the patient wanted to lead a stable life at least for the next five to seven years.

Bone marrow stem cells self transplant can reduce Multiple Sclerosis (MS) symptoms, and make the disease regress in some cases.
These are the hopeful results from a research on 21 patients diseased by MS, made by the Chicago Northwestern University School of Medicine and published on Lancet Neurology. “Since 3 years from self transplant all the patients watch their conditions better.”

Since these results, doctors decided to make a bigger research involving more MS diseased people and comparing new therapy’s results with olds’ ones.
The experiment is about taking marrow stem cells and then treating them to remove ill lymphocytes which attack nerve fibers and then causing MS.

Stem cells are ready to create a ‘correct’ immune system and transplant begins after this process. “Time factor” is the nodal point for stem effectiveness because “operating soon we can make the most of the body’s self-regeneration, which can be lost in the long run”. Anyway scientists say also “it’s not the final cure to MS”.